NextCell Pharma AB (STO:NXTCL)

Market Cap	144.81M -40.3%
Revenue (ttm)	11.06M -1.9%
Net Income	-35.14M
EPS	-0.46
Shares Out	111.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	191,681
Average Volume	321,591
Open	1.302
Previous Close	1.302
Day's Range	1.260 - 1.302
52-Week Range	0.630 - 3.600
Beta	0.70
RSI	44.65
Earnings Date	May 28, 2026

About NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 24
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: NXTCL

Financial Performance

In fiscal year 2025, NextCell Pharma AB's revenue was 11.06 million, a decrease of -1.90% compared to the previous year's 11.28 million. Losses were -35.14 million, -16.25% less than in 2024.